This database contains 5 studies, archived under the term: "placebo effect"
Treatment with Huperzine A improves cognition in vascular dementia patients
Xu, Zhi-Qiang,
Liang, Xiao-Min,
Juan, Wu,
Zhang, Yuan-Feng,
Zhu, Chun-Xia,
Jiang, Xiao-Jiang
Unlabelled: In the present study, we tested the efficacy and safety of Huperzine A in treatment of mild to moderate vascular dementia (VaD). This was a randomized, double-blinded, placebo-controlled study with 78 patients with mild to moderate VaD. The participants were randomized to receive either vitamin C (100-mg bid) as placebo (n = 39) or […]
Effects of rivastigmine in Alzheimer’s disease patients with and without hallucinations
Cummings, Jeffrey,
Emre, Murat,
Aarsland, Dag,
Tekin, Sibel,
Dronamraju, Nalina,
Lane, Roger
Hallucinations in Alzheimer’s disease (AD) may indicate greater cortical cholinergic deficits. Rivastigmine has shown larger treatment benefits versus placebo in dementia with Lewy bodies and Parkinson’s disease dementia patients with hallucinations. In this retrospective, hypothesis-generating analysis, we investigated whether hallucinations in AD were associated with greater treatment benefits with rivastigmine. Data were pooled from two […]
Reduced TNF-α and increased IGF-I levels in the serum of Alzheimer’s disease patients treated with the neurotrophic agent cerebrolysin
Alvarez, X. Anton,
Sampedro, Carolina,
Cacabelos, Ramon,
Linares, Carlos,
Aleixandre, Manuel,
García-Fantini, Manuel,
Moessler, Herbert
According to current scientific knowledge, excess tumour necrosis factor-α (TNF-α) and low insulin-like growth factor-I (IGF-I) are pathogenic-risk factors that constitute therapeutic targets for Alzheimer’s disease (AD). Changes in serum TNF-α, total and dissociable IGF-I levels were determined by ELISA in 207 AD patients completing a 24-wk, double-blind, placebo-controlled trial to evaluate the effects of […]
Memantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial
Aarsland, Dag,
Ballard, Clive,
Walker, Zuzana,
Bostrom, Fredrik,
Alves, Guido,
Kossakowski, Katja,
Leroi, Iracema,
Pozo-Rodriguez, Francisco,
Minthon, Lennart,
Londos, Elisabet
Background: Dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD) are common forms of dementia that substantially affect quality of life. Currently, the only treatment licensed for PDD is rivastigmine, and there are no licensed treatments for DLB. We aimed to test the safety and efficacy of the N-methyl D-aspartate (NMDA) receptor antagonist memantine […]